Marianne Pavel

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

Simron Singh, Daniel Halperin, Sten Myrehaug et al. · The Lancet · 2024 · 324 citations · Full text

Medicine, Oncology, Pharmacology +17

Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

Éric Baudin, Martyn Caplin, Rocio García‐Carbonero et al. · Annals of Oncology · 2021 · 256 citations · Full text

Medicine, Oncology, Pathology +14

European Neuroendocrine Tumor Society ( <scp>ENETS</scp> ) 2023 guidance paper for digestive neuroendocrine carcinoma

Halfdan Sørbye, Enrique Grande, Marianne Pavel et al. · Journal of Neuroendocrinology · 2023 · 169 citations · Full text

Medicine, Oncology, Surgery +17

Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial

Marianne Pavel, David J. Gross, Marta Benavent et al. · Endocrine Related Cancer · 2018 · 135 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Impact of Multiphase &lt;sup&gt;68&lt;/sup&gt;Ga-DOTATOC-PET/CT on Therapy Management in Patients with Neuroendocrine Tumors

Juri Ruf, F Heuck, Jan Schiefer et al. · Neuroendocrinology · 2009 · 130 citations

Medicine, Oncology, Radiology +17